News Sentiment

LGND sentiment intelligence

Ligand Pharmaceuticals Incorporated news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 72 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 274.88 Week of 19 Jun 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 65

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+7.6% over one week, +19.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Ligand Pharmaceuticals Incorporated Stock 12‑Month Price Target Raised to $278.5, Implies 1% Upside

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction 7.6% Price confirming higher
Trend fit Trend active 19.9% over four weeks
Fair value 124.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 48
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 65
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 21
Market source 7
simplywall.st 6
MarketBeat 5
TradingView 4
MT Newswires 4
GlobeNewswire 2
Trefis 2

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 16
Deals and strategy 10
Analyst action 4
Guidance 2
Capital return 1
Balance sheet 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 72
TMX Newsfile Direct company coverage

Levi & Korsinsky LLP, National Class Action Law Firm, Announces Class Action Investigation Against Robinhood and Other Brokers on Behalf of Investors in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)

Levi & Korsinsky, LLP has launched an investigation into Robinhood, Interactive Brokers, and other trading platforms following trading bans and forced liquidations affecting investors in Ligand Pharmaceuticals (NASDAQ: LGND). These actions, which occurred on January 28, 2021, and

Tone
Negative 16/100
Event
Regulatory and legal
Published
03 Jun 2026 03:39
Source
TMX Newsfile
Simply Wall Street Direct company coverage

Ligand Pharmaceuticals (Nasdaq:LGND) - Stock Analysis

Ligand Pharmaceuticals (Nasdaq:LGND) is a biopharmaceutical company focused on developing and licensing biopharmaceutical assets. The company recently agreed to acquire XOMA Royalty Corporation for $739 million, significantly expanding its royalty portfolio and leading to an upli

Tone
Positive 71/100
Event
Market update
Published
26 May 2026 11:39
Source
Simply Wall Street
Zacks Small Cap Research Direct company coverage

LGND: XOMA Buy Adds 100+ Assets

Ligand Pharmaceuticals (NASDAQ: LGND) announced the acquisition of XOMA Royalty Corporation (NASDAQ: XOMA) for $739 million, adding over 100 assets to its portfolio. The all-cash transaction, expected to close in Q3 2026, is projected to be immediately accretive to Ligand's earni

Tone
Positive 73/100
Event
Deals and strategy
Published
20 May 2026 21:40
Source
Zacks Small Cap Research
TradingView Direct company coverage

Ligand Pharmaceuticals Amends XOMA Royalty Merger Agreement to Add Holding Company

Ligand Pharmaceuticals has amended its merger agreement with XOMA Royalty to include XOMA Royalty Holdings, facilitating a Nevada holding company reorganization. This change will result in Ligand's Merger Sub merging with HoldCo, which will then become a wholly owned subsidiary o

Tone
Neutral 50/100
Event
Deals and strategy
Published
19 May 2026 09:10
Source
TradingView
Stock Titan Direct company coverage

Ligand (NASDAQ: LGND) amends XOMA Royalty merger, adds Nevada holding company

Ligand Pharmaceuticals (LGND) has amended its merger agreement with XOMA Royalty Corporation to include XOMA Royalty Holdings Corporation as a party, formalizing a Nevada holding company reorganization. This amendment clarifies the legal structure of the previously announced acqu

Tone
Neutral 50/100
Event
Deals and strategy
Published
19 May 2026 09:10
Source
Stock Titan
MarketBeat Direct company coverage

Stephens Investment Management Group LLC Cuts Stock Holdings in Ligand Pharmaceuticals Incorporated $LGND

Stephens Investment Management Group LLC decreased its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 9.6% in the fourth quarter, though it remains its 16th largest holding. Despite positive analyst sentiment and a "Moderate Buy" consensus rating, the company reported mixed qua

Tone
Neutral 50/100
Event
Analyst action
Published
17 May 2026 14:10
Source
MarketBeat
Stock Titan Direct company coverage

Ligand (LGND) Q1 2026 royalty revenue jumps 56% as guidance reaffirmed

Ligand Pharmaceuticals reported strong Q1 2026 results with royalty revenue increasing 56% year-over-year to $43.0 million, primarily driven by products like Filspari, Ohtuvayre, and Capvaxive. Despite a GAAP net loss of $13.3 million due to non-cash items, adjusted net income ro

Tone
Positive 74/100
Event
Earnings
Published
14 May 2026 07:09
Source
Stock Titan
MarketBeat Direct company coverage

UBS Group AG Purchases 31,081 Shares of Ligand Pharmaceuticals Incorporated $LGND

UBS Group AG significantly increased its stake in Ligand Pharmaceuticals, purchasing 31,081 additional shares in the fourth quarter, bringing its total holding to 143,067 shares valued at approximately $27.05 million. This comes amidst mixed analyst sentiment, with several firms

Tone
Positive 67/100
Event
Earnings
Published
12 May 2026 07:39
Source
MarketBeat
Market source Direct company coverage

A Look At Ligand Pharmaceuticals (LGND) Valuation After Earnings Miss XOMA Deal And Viking TR-Beta Termination

Ligand Pharmaceuticals (LGND) recently reported an earnings miss, higher royalty revenues, a planned acquisition of XOMA, and a disputed termination of the Viking TR-Beta licensing program. Despite these developments, the stock has shown positive momentum over the past few months

Tone
Positive 61/100
Event
Deals and strategy
Published
10 May 2026 09:40
Source
Market source
TradingView Direct company coverage

XOMA Royalty to Be Acquired by Ligand in $39-Per-Share Cash Deal Plus CVRs

XOMA Royalty has agreed to be acquired by Ligand Pharmaceuticals for $39.00 per share in cash, plus contingent value rights (CVRs) from RemainCo LLC. The deal awaits HSR clearance and stockholder approval, with key XOMA stakeholders, including BVF Partners, already committed to s

Tone
Positive 73/100
Event
Deals and strategy
Published
07 May 2026 04:09
Source
TradingView
Market source Direct company coverage

Ligand to Participate in May Investor Conferences

Ligand Pharmaceuticals announced its senior management team will participate in several investor conferences throughout May 2026, including the H.C. Wainwright Royalty Company Conference, Bank of America Healthcare Conference, CJS Securities Spring 1x1 Conference, H.C. Wainwright

Tone
Positive 62/100
Event
Market update
Published
05 May 2026 17:39
Source
Market source
Sahm Direct company coverage

Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders?

Halper Sadeh LLC, an investor rights law firm, is investigating the sales of XOMA Royalty Corporation, RE/MAX Holdings, Inc., and KalVista Pharmaceuticals, Inc. The firm is examining potential violations of federal securities laws and breaches of fiduciary duties to shareholders,

Tone
Neutral 50/100
Event
Market update
Published
05 May 2026 02:09
Source
Sahm
Stock Titan Direct company coverage

Vanguard Capital Management files Schedule 13G on Ligand (LGND) showing 5% stake

Vanguard Capital Management has filed a Schedule 13G on Ligand Pharmaceuticals Inc. (LGND), reporting a beneficial ownership of 997,637 shares, which represents a 5% stake in the company's common stock as of March 31, 2026. The filing indicates Vanguard possesses sole dispositive

Tone
Neutral 50/100
Event
Deals and strategy
Published
01 May 2026 12:39
Source
Stock Titan
Stock Titan Direct company coverage

Vanguard reports 5.56% stake in Ligand Pharmaceuticals (NASDAQ: LGND)

Vanguard Portfolio Management has reported a 5.56% beneficial ownership stake in Ligand Pharmaceuticals Inc. (NASDAQ: LGND), holding 1,109,154 shares. The Schedule 13G filing indicates sole voting power over 8,887 shares and sole dispositive power over all 1,109,154 shares. This

Tone
Neutral 50/100
Event
Deals and strategy
Published
01 May 2026 12:39
Source
Stock Titan
Stock Titan Direct company coverage

[8-K] LIGAND PHARMACEUTICALS INC Reports Material Event

Ligand Pharmaceuticals Inc. (LGND) filed an 8-K report announcing the termination of the TR-Beta Program under its Master License Agreement with Viking Therapeutics, Inc., effective May 4, 2026. Ligand asserts that Viking materially breached its obligation to use commercially rea

Tone
Negative 37/100
Event
Market update
Published
30 Apr 2026 21:09
Source
Stock Titan
MarketBeat Direct company coverage

B. Metzler seel. Sohn & Co. AG Invests $1.30 Million in Ligand Pharmaceuticals Incorporated $LGND

B. Metzler seel. Sohn & Co. AG has invested $1.30 million in Ligand Pharmaceuticals (NASDAQ:LGND) by purchasing 6,879 shares in Q4, bringing institutional ownership to approximately 91.28%. Despite this, company insiders, including the CFO and a director, have recently sold share

Tone
Positive 70/100
Event
Market update
Published
28 Apr 2026 00:39
Source
MarketBeat
TradingView Direct company coverage

Ligand Pharmaceuticals to Acquire XOMA Royalty for $39 Per Share Plus CVRs

Ligand Pharmaceuticals has entered into a definitive merger agreement to acquire XOMA Royalty for $39.00 per share in cash, along with contingent value rights (CVRs) tied to a CVR Trust. The deal is contingent on XOMA Royalty stockholder approval, HSR clearance, and a holding com

Tone
Neutral 50/100
Event
Deals and strategy
Published
28 Apr 2026 00:39
Source
TradingView
Stock Titan Direct company coverage

Ligand (Nasdaq: LGND) to acquire XOMA Royalty in $739M, EPS‑accretive deal

Ligand Pharmaceuticals announced its agreement to acquire XOMA Royalty Corporation for $739 million in cash, equating to $39.00 per share plus a contingent value right tied to Janssen litigation proceeds. This acquisition will significantly expand Ligand's biopharma royalty portf

Tone
Positive 73/100
Event
Deals and strategy
Published
28 Apr 2026 00:09
Source
Stock Titan
MarketBeat Direct company coverage

Impax Asset Management Group plc Sells 35,000 Shares of Ligand Pharmaceuticals Incorporated $LGND

Impax Asset Management Group plc reduced its stake in Ligand Pharmaceuticals Incorporated by 17.5%, selling 35,000 shares and now holding 165,208 shares valued at approximately $31.24 million. Despite this sale, Ligand Pharmaceuticals reported strong quarterly results with EPS of

Tone
Positive 61/100
Event
Earnings
Published
25 Apr 2026 13:10
Source
MarketBeat
MarketBeat Direct company coverage

Assetmark Inc. Raises Holdings in Ligand Pharmaceuticals Incorporated $LGND

Assetmark Inc. significantly increased its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 4,933.3%, now owning 6,191 shares valued at approximately $1.17 million. Analysts maintain a "Moderate Buy" consensus with a price target of $247.29, following strong quarterly earnings wh

Tone
Positive 75/100
Event
Earnings
Published
22 Apr 2026 10:08
Source
MarketBeat